A groundbreaking study suggests that inexpensive drugs already in use by the NHS could play a pivotal role in preventing the spread of breast cancer.Researchers at the University of Virginia have discovered a potential connection between an imbalance in gut microbiota and the progression of breast cancer.

The study highlights how an overgrowth of harmful bacteria in the gut can lead to elevated bile acid levels, which may trigger inflammation in breast tissue and accelerate cancer metastasis.

By administering bile-suppressing medications to mice and human patients, researchers observed prolonged survival rates among those with advanced-stage disease.The findings imply that existing NHS drugs could be repurposed to not only treat but potentially prevent breast cancer spread.This development is particularly significant given that breast cancer affects nearly 60,000 women annually in the UK.The research underscores the importance of gut health in oncology and opens new avenues for therapeutic interventions.

While further clinical trials are needed, the study offers hope for more affordable and accessible treatment options, aligning with the NHS's commitment to innovative healthcare solutions.